相关临床试验
49
3 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1365
进行中（未招募）
1
2.0%
已完成
19
38.8%
Enrolling By Invitation
1
2.0%
尚未招募
1
2.0%
招募中
15
30.6%
终止
1
2.0%
Unknown
11
22.4%
暂无批准数据
- Japanese AI drug discovery company Elix and the University of Vienna have signed a joint research agreement to accelerate drug discovery using AI technologies. - The partnership combines Elix's AI-driven molecular generation platform with the Orts Lab's pioneering NMR spectroscopy techniques for atomic-resolution structural biology. - The collaboration specifically targets intrinsically disordered proteins and proteins implicated in epigenetic signaling and cancer, aiming to address traditionally "undruggable" targets. - The project seeks to integrate AI's predictive power with experimental atomic-resolution data to deliver next-generation therapeutic candidates for complex diseases.
- Researchers at the University of Vienna have developed a method to directly and selectively modify N-methylamines, a key class of molecules in pharmaceuticals, without complex multi-step syntheses. - The "Alkyl Swap" technique uses simple alkenes to replace methyl groups on amines with more complex fragments under surprisingly mild, robust conditions dubbed "bathtub chemistry." - The method was successfully demonstrated on derivatives of well-known drugs including fluoxetine, duloxetine, sertraline, atomoxetine, and citalopram, enabling single-step synthesis of commercially important drugs. - This breakthrough could dramatically accelerate modern drug research by enabling rapid generation of hundreds of molecular variants for testing, as well as late-stage modification of complex drug molecules and peptide-drug conjugates.
- A U.S. appeals court has vacated a 2022 patent ruling, reopening the dispute over who first invented CRISPR gene editing in human cells between Nobel laureates Doudna/Charpentier and the Broad Institute's Feng Zhang. - The court determined that the Patent Trial and Appeal Board applied the wrong legal standard, stating inventors don't need to "know their invention would work" to get credit for conceiving it. - The decision could potentially redirect billions in licensing revenues and redefine patent law standards for invention conception, with implications extending beyond the 13-year CRISPR patent saga.
- The U.S. Court of Appeals for the Federal Circuit has partially vacated the Patent Trial and Appeal Board's previous decision in the CRISPR/Cas9 patent interference case, remanding it for further review. - Editas Medicine maintains confidence in its intellectual property portfolio, emphasizing that the decision does not affect existing licenses or its ability to license foundational CRISPR patents. - The company holds extensive patents covering CRISPR/Cas9 and CRISPR/Cas12a gene editing in human cells, with only a fraction involved in the ongoing interference proceedings.
